'Magical' Blue Flower Changing Farmers' Fortunes in India

The butterfly pea grows wild across India. (Shutterstock)  
The butterfly pea grows wild across India. (Shutterstock)  
TT

'Magical' Blue Flower Changing Farmers' Fortunes in India

The butterfly pea grows wild across India. (Shutterstock)  
The butterfly pea grows wild across India. (Shutterstock)  

“Until a few years ago, the butterfly pea flower was just another climbing plant in my village,” said Nilam Brahma who lives in Anthaigwlao, a village in the northeastern Indian state of Assam.

Butterfly pea, also known as aparajita in India, grows as a vine and has a striking blue flower.

Around two years ago, Brahma heard that local women were making money selling the flowers, which can be made into tea, or a blue dye, according to BBC.

She decided to join them.

“The results surprised even me. The first time I earned $50 from selling dried flowers, I felt a shock. It made me believe I could control my own future,” she said.

The experiment led to a small business.

“I applied for a small loan and invested in solar dryers. The machines helped me dry flowers faster, preserve their color, and meet the quality standards demanded by buyers,” Brahma added.

Thailand and Indonesia have been the leading growers and consumers of butterfly pea flowers. But there's growing global demand for the flower, which is attracting entrepreneurs in India.

“The global demand for natural colorants is exploding,” explained Varshika Reddy, the founder of THS Impex, which exports natural dyes and additives.

Behind that demand is consumer appetite for natural ingredients and tighter controls in the US and Europe on synthetic food dyes.

In 2021, the US Food and Drug Administration (FDA) approved butterfly pea flower as a food additive.

However, in 2022 the European Food Safety Authority (EFSA) raised safety concerns about using the flower.

Both the EU and the UK classify butterfly pea flower as a "novel" food, meaning it still needs approval for widespread use.

Nevertheless, Indian entrepreneurs still see potential and want to develop India's market.

“The crop is still seen as a backyard ornamental or medicinal plant rather than a commercial commodity,” said Reddy. “There is no structured market awareness, no government classification, and no standard pricing mechanism, making farmers uncertain about returns.”

She is working with farmers to raise production standards.

“We work with a dedicated cluster of farmers and their families in Uttar Pradesh, including a significant number of women farmers. We have established formal contracts... we provide comprehensive agronomy support, including guidance on best farming practices, irrigation management, and crop-specific techniques,” Reddy said.

Others in India have spotted the commercial opportunity.

“When you infuse the flower in hot water, it turns blue, and when you squeeze lemon into it, it turns purple. That felt magical,” said Nitesh Singh, who is based just outside Delhi.

Like Reddy, he thought that the flower had much more potential in India.

“It was here for thousands of years, but nobody knew it could become clean, healthy food,” Singh added.



Japan Approves Stem-cell Treatment for Parkinson's in World First

Parkinson's disease. John SAEKI, Adrian LEUNG / AFP
Parkinson's disease. John SAEKI, Adrian LEUNG / AFP
TT

Japan Approves Stem-cell Treatment for Parkinson's in World First

Parkinson's disease. John SAEKI, Adrian LEUNG / AFP
Parkinson's disease. John SAEKI, Adrian LEUNG / AFP

Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports said Friday, with the therapies expected to reach patients within months.

Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson's disease treatment that transplants stem cells into a patient's brain, said AFP.

Japan's health ministry also gave the go-ahead to ReHeart, heart muscle sheets developed by medical startup Cuorips that can help form new blood vessels and restore heart function, media reports said.

The treatments could be on the market and rolled out to patients as early as this summer, reports said, citing the health ministry, becoming the world's first commercially available medical products using (iPS) cells.

Japanese scientist Shinya Yamanaka won the Nobel Prize in 2012 for his research into iPS, which have the potential to develop into any cell in the body.

"I hope this will bring relief to patients not only in Japan but around the world," health minister Kenichiro Ueno told a press conference.

"We will promptly carry out all necessary procedures to ensure it reaches all patients without fail."

In a statement, Sumitomo Pharma said it had obtained "conditional and time-limited approval" for the manufacture and marketing of Amchepry under a system which is reportedly designed to get these products to patients as quickly as possible.

The approval is a kind of "provisional license", the Asahi newspaper said, after the safety and efficacy of the treatment was judged based on data from fewer patients than in ordinary clinical trials for drugs.

A trial led by Kyoto University researchers indicated that the company's treatment was safe and successful in improving symptoms.

The study involved seven Parkinson's patients aged between 50 and 69, with each receiving a total of either five million or 10 million cells implanted on both sides of the brain.

The iPS cells from healthy donors were developed into the precursors of dopamine-producing brain cells, which are no longer present in people with Parkinson's disease.

The patients were monitored for two years and no major adverse effects were found, the study said. Four patients showed improvements in symptoms.

Parkinson's disease is a chronic, degenerative neurological disorder that affects the body's motor system, often causing shaking and other difficulties in movement.

Worldwide, about 10 million people have the illness, according to the Parkinson's Foundation.

Currently available therapies "improve symptoms without slowing or halting the disease progression," the foundation says.

iPS cells are created by stimulating mature, already specialized, cells back into a juvenile state -- basically cloning without the need for an embryo.

The cells can be transformed into a range of different types of cells, and their use is a key sector of medical research.


Saudi Red Sea Authority Appoints Dr. Maryam Ali Ficociello as CEO

The Saudi Red Sea Authority (SRSA) logo
The Saudi Red Sea Authority (SRSA) logo
TT

Saudi Red Sea Authority Appoints Dr. Maryam Ali Ficociello as CEO

The Saudi Red Sea Authority (SRSA) logo
The Saudi Red Sea Authority (SRSA) logo

The Saudi Red Sea Authority (SRSA) has appointed Dr. Maryam Ali Ficociello as Chief Executive Officer effective March 22.

“Ficociello brings more than two decades of leadership experience spanning governance, risk management, resilience, and compliance across public and private sectors, including state-owned entities. She has also represented the Kingdom at various international forums,” SRSA said in a statement on Thursday.

Commenting on her appointment, Ficociello said: “It is an honor to join the Saudi Red Sea Authority at this pivotal stage in its journey. SRSA has a critical role in enabling a world-class coastal tourism sector that is safe, well-governed, and investment-ready, while protecting the Red Sea’s unique marine ecosystems.”

“I look forward to working with our stakeholders across government and industry to strengthen regulatory excellence, embed sustainability and resilience across the sector, and advance the Kingdom’s ambitions for responsible coastal tourism and the blue economy,” she added.


Tourism on Hold as Middle East War Casts Uncertainty

Tourism to the Middle East has boomed in recent years but war now threatens that success. Ryan Lim / AFP
Tourism to the Middle East has boomed in recent years but war now threatens that success. Ryan Lim / AFP
TT

Tourism on Hold as Middle East War Casts Uncertainty

Tourism to the Middle East has boomed in recent years but war now threatens that success. Ryan Lim / AFP
Tourism to the Middle East has boomed in recent years but war now threatens that success. Ryan Lim / AFP

Cancelled flights, postponed trips and a great deal of uncertainty: the war in the Middle East is casting a long shadow over the tourism outlook for a region that has become a prized destination for travelers worldwide.

"My last group of tourists left three days ago, and all the other groups planned for March have been cancelled," said Nazih Rawashdeh, a tour guide near Irbid, in northern Jordan.

"This is the start of the high season here. It's catastrophic," he told AFP.

"And yet there's no problem in Jordan. It's perfectly safe."

Across the world, tour operators are scrambling to find solutions for clients stranded in the region or who had trips planned there.

"The priority is getting those already there back home," said Alain Capestan, president of the French tour operator Comptoir des Voyages.

He said however that the war is also affecting customers who have travelled to other parts of the world, as the Gulf region is home to several major aviation hubs.

Like other companies, the German tour operators surveyed by AFP -- Alltours, Dertour, Schauinsland-Reisen -- announced they would cover the cost of extra nights for clients stranded in the Middle East. They also cancelled trips to the UAE and Oman until at least March 7.

The British travel industry association ABTA said agencies "would not be sending customers to the region for as long as the British Foreign Office advises against all non-essential travel".

Customers whose holidays were cancelled in recent days will be able to rebook or receive a refund, it said.

- Economic impact -

The war is disrupting a sector that had been booming in the region.

According to UN Tourism, in 2025 around 100 million tourists visited the Middle East -- nearly seven percent of all international tourists recorded worldwide. That figure had grown three percent year-on-year and 39 percent compared to the pre-pandemic period.

Depending on the destination, Europeans make up a large share of visitors, followed by tourists from South Asia, the Americas, and other Middle Eastern countries.

For example, nearby markets accounted for 26 percent of total visitors to Dubai in 2025, according to its Ministry of Tourism and Economy.

Against this backdrop analysts Oxford Economics warns that "a decline in tourist flows to the region will deal a more severe economic blow than in the past, as tourism's share of GDP has grown, as has employment in the sector".

"We estimate inbound arrivals to the Middle East could decline 11-27 percent year-on-year in 2026 due to the conflict, compared to our December forecast that projected 13 percent growth," said Director of Global Forecasting Helen McDermott.

That would translate, according to the firm, to between 23 and 38 million fewer international visitors compared to the prior scenario, and a loss of $34 to $56 billion in tourist spending.

After Covid and then the conflict in Gaza, tourists had been coming back, said Rawashdeh, the Jordanian tour guide.

"For the past six months, people working in tourism here had hope. And now there's a war. This is going to be terrible for the economy," he said.

"We've definitely noticed an understandable slowdown in new bookings from our partners right now, but we fully expect that to bounce back as soon as things settle down and travelers feel more confident," said Ibrahim Mohamed, marketing director of Middle East Travel Alliance, which offers direct tours to American and British operators.

He remains optimistic: "The Middle East has always been an incredibly resilient market, and demand always bounces back fast once stability returns."